Destiny Pharma PLC Destiny Pharma appoints Dr Yuri Martina as CMO (8807J)
03 May 2022 - 4:00PM
UK Regulatory
TIDMDEST
RNS Number : 8807J
Destiny Pharma PLC
03 May 2022
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Destiny Pharma s trengthens Executive Management Team w ith t he
a ppointment o f Dr Yuri Martina a s Chief Medical Officer
Brighton, United Kingdom - 3(rd) May 2022 - Destiny Pharma plc
(AIM:DEST), a clinical stage innovative biotechnology company
focused on the development of novel medicines that can prevent
life-threatening infections, today announces the appointment of Dr.
Yuri Martina as Chief Medical Officer (CMO).
Yuri brings to Destiny Pharma more than 20 years' experience and
an extensive record of excellence in clinical development and
successful interactions at the highest levels with key regulatory,
industry and government stakeholders including the European
Medicines Agency (EMA), the US Food and Drug Administration (FDA)
and the Japanese Pharmaceutical and Medical Device Agency
(PMDA).
Most recently, Yuri was Senior Vice President Development and
deputy CMO at Grünenthal Group where he was a key member of the
Global R&D Leadership and the Global Commercial Leadership
Teams. Yuri has been responsible for advancing the Grünenthal Group
R&D pipeline, including two phase 3 assets, two phase 2 assets
and several early and pre-clinical assets. Yuri has also been a key
member and driver in several in-licensing and out-licensing
activities and in the completion of the acquisition of Mestex
AG.
From 2014 to 2017, Yuri was Vice President Development and
Clinical Operations in Shionogi Europe, where he was a key
contributor to the approval of Mulpeo (previously Lusutrombopag)
and Cefiderocol.
Throughout his career, Yuri has gained a deep insight into
global markets, working in Europe, the US, Middle East and Asia and
has contributed to more than ten submissions for Marketing
Authorisation Applications (MAA) to the EMA and New Drug
Applications (NDA) to the FDA.
Yuri is a Medical Doctor by background, and also holds a PhD in
Genetics and Molecular Biology, an MBA and a Master's in Project
Management. Yuri is also a fellow member of the Royal Society of
Medicine.
Neil Clark, Chief Executive Officer, Destiny Pharma said: "Yuri
is an important new member of our team, as he brings the right
skill sets to drive the strategy, direction and execution of the
Company's Phase 3 clinical development plans as we move towards the
next phase of our growth."
Dr. Yuri Martina, Chief Medical Officer, Destiny Pharma, said:
"I very much look forward to being an integral part of Destiny
Pharma's leadership management team at such a pivotal moment in the
Company's history. I feel privileged to be able to contribute to
progressing the pipeline of our unique late-stage clinical assets
addressing patients' unmet needs and delivering on the Company's
strategy to build a world-leading infection prevention
company."
ENDS
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark / Manel Mateus /Vici Rabbetts
+44 (0) 208 078 4357
DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Kate Bannatyne / George Dollemore, Corporate
Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SporCov, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information on the company, please visit
www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFIFSASIIAFIF
(END) Dow Jones Newswires
May 03, 2022 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024